Safety and Pharmacokinetic Profile of CKD-581 (CKD-581)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2015 by Chong Kun Dang Pharmaceutical
Information provided by (Responsible Party):
Chong Kun Dang Pharmaceutical Identifier:
First received: April 16, 2012
Last updated: July 30, 2015
Last verified: July 2015
This study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), safety and pharmacokinetics (PK) profile of a single agent CKD-581 injection in patients with Lymphoma failed to standard therapy. The usefulness of the this regimen is evaluated by response rate, progression free survival.

Condition Intervention Phase
Multiple Myeloma
Drug: CKD-581
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Clinical Trial to Assess the Safety and Pharmacokinetic Profile of CKD-581 in Patients With Lymphoma or Multiple Myeloma Failed to Standard Therapy

Resource links provided by NLM:

Further study details as provided by Chong Kun Dang Pharmaceutical:

Primary Outcome Measures:
  • Maximum Tolerated Dose [ Time Frame: Up to 28 days (For 1st cycle) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Dose Limiting Toxicity [ Time Frame: Up to 28 days (For 1st cycle) ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics [ Time Frame: 0, 0.25, 1, 1.5, 2, 2.25, 2.5, 3, 3.5, 4, 6, 8, 12, 24 hrs post dose(1st cycle Day1, 15) ] [ Designated as safety issue: No ]
    PK parameters(AUC, Cmax) of CKD-581 & metabolites

  • Objective response rate [ Time Frame: every 56 days (every 2 cycle) ] [ Designated as safety issue: No ]
  • Progression Free survival [ Time Frame: up to progression ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: May 2012
Estimated Study Completion Date: October 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
Drug: CKD-581
CKD-581 qd for Day 1, 8 and 15 every 28days/Cycle
Other Name: Histone Deacetylase Inhibitor

Detailed Description:
Recently, the role of transcriptional repression through epigenetic modulation in carcinogenesis has been clinically validated with several inhibitors of histone deacetylases and DNA methyltransferases. It has long been recognized that epigenetic alterations of tumor suppressor genes was one of the contributing factors in carcinogenesis. Inhibitors of histone deacetylase (HDAC) de-repress genes that subsequently result in growth inhibition, differentiation and apoptosis of cancer cells. CKD-581 is developed for HDAC inhibitors. Such as to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), safety and pharmacokinetics (PK) profile of a single agent CKD-581 injection in patients with Lymphoma failed to standard therapy.

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 20 years and older
  • Histologically or cytologically confirmed Lymphoma or Multiple myeloma that have failed to standard therapy or for which no life prolonging treatment exists
  • ECOG(Eastern cooperative oncology) performance status ≤ 2
  • Life expectancy 12 weeks
  • Hematopoietic: ANC(Absolute Neutrophil Count) ≥ 1,500/mm3, Platelet count(PLT) ≥ 100,000/mm3, Hemoglobin ≥ 9.0g/dL
  • Hepatic: Total bilirubin > 1.5×upper limit of normal(except Gilbert's syndrome patients), aspartate aminotransferase(AST) > 3×upper limit of normal, alanine aminotransferase(ALT) > 3×upper limit of normal(AST, ALT ≤ 5.0×ULN in case of liver metastases)
  • Renal: serum creatinine ≤ 1.5×upper limit of normal
  • Serum calcium ≤ upper limit of normal (If the Multiple myeloma only)
  • Signed a written informed consent

Exclusion Criteria:

  • Have symptoms with Brain metastases
  • History of Ischemic heart disease(e.g., myocardial infarction, unstable angina pectoris) or Clinically significant heart disease such as NYHA Class III and IV Congestive atrial arrhythmias, within 6 months prior to first dose of study drug
  • Acute infection or blooding tendencies that would preclude study compliance
  • Other psychiatric disorders or other conditions that would preclude study compliance
  • Receiving antitumor therapy(surgery, immunotherapy or chemotherapy) within 4 weeks prior to first dose of study drug(6 weeks for nitrosoureas and mitomycin C, 2 weeks for radiation therapy)
  • Other concurrent antitumor therapy
  • Have Cardiac disease by nature
  • Administration history of Histone Deacetylase Inhibitor
  • History of Serious hypersensitivity or allergy
  • Pregnant or nursing, active serum pregnancy test. Fertile patients must use effective contraception
  • Participation in a clinical trial within 4 weeks of first dose of study drug
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01580371

Contact: Dok Hyun Yoon, Ph.D 82-2-3010-5940

Korea, Republic of
ASAN Medical Center Recruiting
Seoul, Korea, Republic of
Contact: Dok Hyun Yoon, Ph.D    82-2-3010-5940   
Principal Investigator: Dok Hyun Yoon, Ph.D         
Sponsors and Collaborators
Chong Kun Dang Pharmaceutical
Study Chair: Dok Hyun Yoon, Ph.D 88,Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea
  More Information

Responsible Party: Chong Kun Dang Pharmaceutical Identifier: NCT01580371     History of Changes
Other Study ID Numbers: 133HL/NHL11L 
Study First Received: April 16, 2012
Last Updated: July 30, 2015
Health Authority: Korea: Ministry of Food and Drug Safety

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Vascular Diseases
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 23, 2016